Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2020
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trialS Dent, J Cortés, Y-H Im, et al.
Leukemia|August 22, 2003
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimenM Mohty, W Jacot, C Faucher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
ESMO Open|July 24, 2025
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implicationsG Griguolo, M V Dieci, S Fineberg, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
ESMO Open|June 4, 2026
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trialC Blaye, F-C Bidard, L Hue, et al.
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Pageof 4